Drygin Denis 4
4 · Regulus Therapeutics Inc. · Filed Feb 5, 2021
Insider Transaction Report
Form 4
Drygin Denis
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-02-04+120,000→ 120,000 totalExercise: $1.59Exp: 2031-02-04→ Common Stock (120,000 underlying)
Footnotes (1)
- [F1]The stock option commenced vesting on January 1, 2021 and will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.